Assuntos
Pesquisa Biomédica , COVID-19 , Coronavirus , Organização do Financiamento , National Institutes of Health (U.S.) , Humanos , Pesquisa Biomédica/economia , Pesquisa Biomédica/legislação & jurisprudência , Pesquisa Biomédica/tendências , COVID-19/epidemiologia , COVID-19/transmissão , COVID-19/virologia , National Institutes of Health (U.S.)/economia , National Institutes of Health (U.S.)/legislação & jurisprudência , Política , Estados Unidos , Zoonoses Virais/epidemiologia , Zoonoses Virais/transmissão , Zoonoses Virais/virologia , AnimaisAssuntos
COVID-19 , National Institutes of Health (U.S.) , Apoio à Pesquisa como Assunto , Criança , Humanos , COVID-19/complicações , COVID-19/economia , Administração Financeira , National Institutes of Health (U.S.)/economia , Estados Unidos , Apoio à Pesquisa como Assunto/economia , Apoio à Pesquisa como Assunto/organização & administraçãoAssuntos
Ensaios Clínicos como Assunto , Terapia por Exercício , National Institutes of Health (U.S.) , Síndrome Pós-COVID-19 Aguda , Apoio à Pesquisa como Assunto , Humanos , National Institutes of Health (U.S.)/economia , National Institutes of Health (U.S.)/organização & administração , Síndrome Pós-COVID-19 Aguda/terapia , Apoio à Pesquisa como Assunto/métodos , Apoio à Pesquisa como Assunto/organização & administração , Estados Unidos , Terapia por Exercício/efeitos adversosAssuntos
Centers for Disease Control and Prevention, U.S./economia , National Institutes of Health (U.S.)/economia , Política , United States Food and Drug Administration/economia , COVID-19/economia , COVID-19/prevenção & controle , Centers for Disease Control and Prevention, U.S./organização & administração , Humanos , National Institutes of Health (U.S.)/organização & administração , Estados Unidos , United States Food and Drug Administration/organização & administraçãoAssuntos
Vacina de mRNA-1273 contra 2019-nCoV , Dissidências e Disputas , Indústria Farmacêutica , Inventores/legislação & jurisprudência , National Institutes of Health (U.S.) , Patentes como Assunto/legislação & jurisprudência , Pesquisadores/legislação & jurisprudência , Vacina de mRNA-1273 contra 2019-nCoV/economia , Vacina de mRNA-1273 contra 2019-nCoV/genética , Vacina de mRNA-1273 contra 2019-nCoV/provisão & distribuição , Indústria Farmacêutica/economia , Indústria Farmacêutica/legislação & jurisprudência , Humanos , Inventores/economia , National Institutes of Health (U.S.)/economia , National Institutes of Health (U.S.)/legislação & jurisprudência , Propriedade/economia , Propriedade/legislação & jurisprudência , Parcerias Público-Privadas/economia , Parcerias Público-Privadas/legislação & jurisprudência , Pesquisadores/economia , SARS-CoV-2/genética , Estados UnidosAssuntos
COVID-19 , Diplomacia , Liderança , National Institutes of Health (U.S.)/organização & administração , Racismo/prevenção & controle , Pesquisa Biomédica/economia , Pesquisa Biomédica/legislação & jurisprudência , Pesquisa Biomédica/organização & administração , COVID-19/complicações , COVID-19/epidemiologia , China , Feminino , Pesquisa Fetal/legislação & jurisprudência , Organização do Financiamento , Humanos , Cooperação Internacional , Masculino , National Institutes of Health (U.S.)/economia , Apoio à Pesquisa como Assunto , Estados Unidos , Síndrome Pós-COVID-19 AgudaAssuntos
Animais de Laboratório , COVID-19/epidemiologia , Modelos Animais de Doenças , Governo Federal , Investimentos em Saúde , Primatas , Apoio à Pesquisa como Assunto , Direitos dos Animais , Animais , Animais de Laboratório/virologia , COVID-19/virologia , Callithrix , Organização do Financiamento , Abrigo para Animais/economia , Humanos , Macaca mulatta/genética , Macaca mulatta/virologia , National Institutes of Health (U.S.)/economia , Papio , Primatas/virologia , SARS-CoV-2/patogenicidade , SARS-CoV-2/fisiologia , Estados UnidosRESUMO
In the wake of the COVID-19 pandemic, the need for rapid and accurate diagnostic testing across populations quickly became evident. In response, the National Institutes of Health (NIH) was determined not only to invest heavily in this area but to change the process by which grant proposals were reviewed and funded in order to spur faster development of viable technologies. The Rapid Acceleration of Diagnostics (RADx) initiative was designed to speed innovation, commercialization, and implementation of potential COVID-19 diagnostic technology. As part of this effort, the RADx Tech initiative focuses on the development, validation, and commercialization of innovative point-of-care, home-based, and clinical lab-based tests that can detect SARS-CoV-2. This effort was enabled through the NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB) Point-of-Care Technology Research Network (POCTRN).
Assuntos
Engenharia Biomédica/economia , Teste para COVID-19/economia , COVID-19 , National Institutes of Health (U.S.)/economia , Pandemias , Sistemas Automatizados de Assistência Junto ao Leito/economia , SARS-CoV-2 , Engenharia Biomédica/tendências , COVID-19/diagnóstico , COVID-19/economia , COVID-19/epidemiologia , Humanos , Estados UnidosAssuntos
Pesquisa Biomédica/economia , Pesquisa Biomédica/tendências , COVID-19/complicações , Objetivos , National Institutes of Health (U.S.)/economia , Apoio à Pesquisa como Assunto/economia , Ansiedade , Autopsia , Bancos de Espécimes Biológicos/organização & administração , COVID-19/epidemiologia , COVID-19/patologia , COVID-19/fisiopatologia , COVID-19/terapia , Depressão , Suscetibilidade a Doenças , Dispneia , Fadiga , Febre , Humanos , Estudos Longitudinais , Monitorização Fisiológica , National Institutes of Health (U.S.)/organização & administração , Especificidade de Órgãos , Apoio à Pesquisa como Assunto/organização & administração , Fatores de Tempo , Estados Unidos , Síndrome Pós-COVID-19 AgudaRESUMO
The federal spending bill enacted by the U.S. Congress in December for fiscal year 2021 totals $1.4 trillion, plus another $900 billion in emergency COVID-19 relief funding. The $1.4 trillion includes budget increases for the NIH, NCI, and FDA that help the agencies keep pace with inflation. Research advocates say more than $10 billion in emergency supplemental funds for the NIH is urgently needed to support medical research affected by the COVID-19 pandemic.
Assuntos
Pesquisa Biomédica/legislação & jurisprudência , Governo Federal , Política de Saúde , Neoplasias/terapia , Apoio à Pesquisa como Assunto , Pesquisa Biomédica/economia , COVID-19/economia , Vacinas contra COVID-19/economia , Humanos , Oncologia/organização & administração , National Cancer Institute (U.S.)/economia , National Institutes of Health (U.S.)/economia , Neoplasias/economia , Sociedades Médicas , Estados Unidos , United States Food and Drug Administration/economiaRESUMO
BACKGROUND: The US faces remarkable food and nutrition challenges. A new federal effort to strengthen and coordinate nutrition research could rapidly generate the evidence base needed to address these multiple national challenges. However, the relevant characteristics of such an effort have been uncertain. OBJECTIVES: Our aim was to provide an objective, informative summary of 1) the mounting diet-related health burdens facing our nation and corresponding economic, health equity, national security, and sustainability implications; 2) the current federal nutrition research landscape and existing mechanisms for its coordination; 3) the opportunities for and potential impact of new fundamental, clinical, public health, food and agricultural, and translational scientific discoveries; and 4) the various options for further strengthening and coordinating federal nutrition research, including corresponding advantages, disadvantages, and potential executive and legislative considerations. METHODS: We reviewed government and other published documents on federal nutrition research; held various discussions with expert groups, advocacy organizations, and scientific societies; and held in-person or phone meetings with >50 federal staff in executive and legislative roles, as well as with a variety of other stakeholders in academic, industry, and nongovernment organizations. RESULTS: Stark national nutrition challenges were identified. More Americans are sick than are healthy, largely from rising diet-related illnesses. These conditions create tremendous strains on productivity, health care costs, health disparities, government budgets, US economic competitiveness, and military readiness. The coronavirus disease 2019 (COVID-19) outbreak has further laid bare these strains, including food insecurity, major diet-related comorbidities for poor outcomes from COVID-19 such as diabetes, hypertension, and obesity, and insufficient surveillance on and coordination of our food system. More than 10 federal departments and agencies currently invest in critical nutrition research, yet with relatively flat investments over several decades. Coordination also remains suboptimal, documented by multiple governmental reports over 50 years. Greater harmonization and expansion of federal investment in nutrition science, not a silo-ing or rearrangement of existing investments, has tremendous potential to generate new discoveries to improve and sustain the health of all Americans. Two identified key strategies to achieve this were as follows: 1) a new authority for robust cross-governmental coordination of nutrition research and other nutrition-related policy and 2) strengthened authority, investment, and coordination for nutrition research within the NIH. These strategies were found to be complementary, together catalyzing important new science, partnerships, coordination, and returns on investment. Additional complementary actions to accelerate federal nutrition research were identified at the USDA. CONCLUSIONS: The need and opportunities for strengthened federal nutrition research are clear, with specific identified options to help create the new leadership, strategic planning, coordination, and investment the nation requires to address the multiple nutrition-related challenges and grasp the opportunities before us.